Price
962
-0.99%52W Range
Market Cap
₹10,865.66 Cr
Traded: ₹18.90 Cr (0.17%) 0.0x
Free Float: ₹309.67 Cr (6.10% of FF traded)
Volume · 60D trend
1.96 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +24.0% | -- | -- | +28.0% | Accelerating |
| Profit | -- | +39.0% | -- | -- | +25.0% | Decelerating |
| Return | -- | -- | -- | -- | -- | -- |
| ROE | -- | -- | +30.0% | -- | -- | -- |
Quarterly Results
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales | 158 | 182 | 172 | 163 | 125 | 158 | 116 | 149 |
| Expenses | 103 | 120 | 112 | 107 | 81 | 99 | 76 | 85 |
| Operating Profit | 55 | 63 | 60 | 55 | 44 | 59 | 39 | 63 |
| Other Income | 5 | 6 | 7 | 10 | 5 | 4 | 2 | 2 |
| Interest | 2 | 2 | 1 | 2 | 2 | 2 | 1 | 1 |
| Depreciation | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 3 |
| Profit Before Tax | 54 | 63 | 62 | 60 | 44 | 58 | 38 | 62 |
| Tax % | 25.0% | 23.0% | 23.0% | 21.0% | 29.0% | 24.0% | 24.0% | 21.0% |
| Net Profit | 41 | 49 | 48 | 47 | 31 | 44 | 29 | 49 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 3.6 | 4.3 | 4.2 | 4.7 | 3.2 | 4.5 | 3.0 | 128.1 |
| Sales Growth (YoY) | -- | 15.7% | 49.2% | 9.3% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 5.8% | 5.5% | 30.4% | -20.9% | 36.2% | -22.1% | -- |
| OP Growth (YoY) | 25.0% | 6.8% | 53.8% | -12.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | -12.7% | 5.0% | 9.1% | 25.0% | -25.4% | 51.3% | -38.1% | -- |
| Profit Growth (YoY) | -- | 10.6% | 65.3% | -6.2% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -4.6% | 42.4% | -96.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 3.1% | -10.8% | 48.6% | -30.2% | 53.9% | -97.7% | -- |
| OP Margin | -- | 34.6% | 34.9% | 33.7% | 35.2% | 37.3% | 33.6% | 42.3% |
| Net Margin | -- | 26.9% | 27.9% | 28.8% | 24.8% | 27.9% | 25.0% | 32.9% |
| Material Cost % | -- | 35.0% | 34.9% | 37.5% | 33.9% | 37.9% | 32.9% | 33.4% |
| Employee Cost % | -- | 5.8% | 8.7% | 8.7% | 9.8% | 6.9% | 8.4% | 6.2% |
| P/S | 16.07 | 15.34 | 12.75 | -- | -- | -- | -- | -- |
| P/E | 57.16 | 53.13 | 43.25 | -- | -- | -- | -- | -- |
| P/B | 12.31 | 11.15 | 10.13 | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation for the Investor Meet Scheduled to be held on 29th October 2026 at 12:00 noon.
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
Submission of Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulation as on 30.09.2026
We wish to inform the changes in the SMP of the Company, arising due to completion of contractual arrangements between the company and Mr. Sendhil Pani, Managing Director of Sudeep Pharma ....
This is to inform that the officials of the Company will be attending the Investor Conference organized by Nuvama Emerging India CEO Forum 2026 on 28th September 2026 at 10:00 a.m. in Mumbai.
Intimation on Cancellation of scheduled Investor /Analyst Meet
we would like to inform that the officials of the Company has arranged a plant visit (Gujarat) for Investors/Analysts (Participants) on 23rd & 24th September 2026.
Submission of Earnings Call Transcript for the call held on 05.08.2026
General Update
Submission of E-voting and Scrutinizer''s Report for the 37th Annual General Meeting held on 04.08.2026
Submission of proceedings of the 37th Annual General Meeting held on 4th August 2026
Submission of Outcome of Board Meeting
Submission of Financials as on 30.06.2026
Intimation for Earnings call to be held on Wednesday, 5th August 2026
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2026 ,inter alia, to consider and approve the unaudited financials (standalone ....
Submission of Newspaper Advertisement for 37th AGM, E-voting and dividend information published in Business Standard (English) and Vadodara Samachar (regional language) on Saturday, 11th July, 2026.
Intimation for 37th Annual General Meeting to be held on Tuesday, 4th August 2026 at 11:00 a.m.
Letter to Shareholders in Relation to Integrated Annual Report of the Company for the Financial Year 2025-26
Submission of Certificate under Regulation 74 (5) of SEBI (DP) Regulations for the Quarter ended 30.06.2026
Record date for payment of final dividend on equity shares for the FY 2025-26 is Thursday, 23rd July, 2026.
Submission of 37th Annual Report
This is to inform that the Board of Directors at their meeting held on 26th June 2026 has appointed Mr. Milin Mehta as an Additional Director of the Company with immediate effect.
This is to inform that, the Board has appointed Mr. Milin Mehta as an Additional Director (Non-Executive & Non-Independent) w.e.f. 26.06.2026.
Intimation for Closure of Trading Window w.e.f. 1St July 2026 for Adoption of un-audited Financial Results for the Quarter ended 30th June 2026.
Submission of Earnings Call Transcript for Q4 FY26.
Submission of Annual Secretarial Compliance Report for FY 2025-26
Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended from time to time, we herewith submit the participation of Company Officials ....
Pursuant to Regulation 30 and 47 of the SEBI LODR Regulation, we hereby submit the copies of the extract of audited financials results of the Company for the 4th Quarter and year ended ....
Submission of Audio Recording of Investor''s Call/Meet held on 22nd May 2026 at 11:00 a.m.
Outcome of Board Meeting held on 21st May 2026
Financial Results for the year ended 31st March 2026.
Submission of Investors Presentation for the year ended 31st March 2026
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2026 ,inter alia, to consider and approve the Audited Standalone and Consolidated ....
Pursuant to Regulation 30 of the SEBI (LODR)Regulations, 2015 the Analysts/Investors meet is Scheduled on Friday, 22nd May 2026 at 11:00 a.m. to discuss the operational & financial performance ....
Submission of Certificate under Regulation 74 (5) of SEBI (DP) Regulations.
Intimation for Closure of Trading Window w.e.f. 1st April 2026
Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be meeting ....
Submission of Earnings Call Transcript for the earnings call held on 9th February 2026 to discuss the operational and financial performance of the Company for the third quarter and nine ....
Submission of Audio Link for the call held on 9th February 2026
Submission of Audio Link for the Investors Call held on 9th February 2026
Pursuant to Regulation 30 of SEBI (LODR), we hereby submit Investor Presentation for the unaudited financials as on third quarter and nine months ended on 31st December 2025
Intimation for Re-schedule of Earnings Call with Analysts/Investors on 09th February 2026 at 11:00 a.m. all the investors are requested to take note of the same.
Pursuant to Regulation 30 and 47 of SEBI (LODR) please find attached newspaper publication for extract of un-audited financial results for the third quarter and nine months ended 31st December 2025.
Submission of unaudited Financial results for the third quarter and nine months ended 31.12.2025
Submission of Unaudited Standalone & Consolidated Financials as on third quarter and nine months ended 31st December 2025
Pursuant to the Regulation 30 of SEBI (LODR) Regulation 2015 we hereby submit that Mr. John Garcia (VP - Sales & Supply Chain) of Sudeep Pharma USA Inc, designated as SMP, vide his letter ....
This is to inform that the 'Earnings Call' of the Company with Analysts/Investors to discuss the operational & financial performance for the quarter and nine ended on December 31, 2025, ....
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
We hereby inform you that the Company''s Wholly Owned Subsidiary i.e. Sudeep Advanced Materials Private Limited has purchased the rights in leasehold land in Dahej, Gujarat (GIDC) from ....
Intimation for update in Corporate Identification Number (CIN) and status of the Company on the MCA portal.
Concalls
2Feb 2026
28 Feb 2026Dec 2025
31 Dec 2025Held by ETFs
1 ETFs hold SUDEEPPHRM · sorted by weight
Held by Mutual Funds
24 schemes hold SUDEEPPHRM · sorted by weight